Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hiya. Today, we explore a gene therapy approach that’s drawing excitement but also skepticism, and see that Jennifer Doudna is moving into AI-designed gene editors that push beyond evolution.
Plus, our trusty podcasters unpack the buzzy prediction market Kalshi’s move into biotech.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
